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Previous experiments in rats have suggested that renal scarring after acute, obstructive
pyelonephritis due to Escherichiacoli results from parenchymal damage due to acute in-
flammation and suppuration. To assess the role of acute infiltration by polymorphonu-
clear leukocytes (PMNLs) in the pathogenesis of chronic pyelonephritis (CPN), rats
were either treated with colchicine to depress leukcoyte motility or rendered neutropen-
ic with a single dose of cyclophosphamide. Colchicine given during acute pyelonephritis
reduced kidney inflammation and protected against CPN two months later. Similarly,
neutropenia reduced acute inflammation and protected against chronic parenchymal
destruction and scarring. Protection against renal scarring in both colchicine-treated
and neutropenic rats occurred despite higher renal bacterial counts during acute
pyelonephritis. These experiments provide further evidence that CPN (renal scarring)
results from kidney damage that occurs during early acute obstructive pyelonephritis.
This damage appears to result from infiltration of the kidney by PMNLs rather than
direct damage from bacterial infection.
The mechanisms that lead to the development of
chronic pyelonephritis (CPN) after acute renal in-
fection are not well defined. Persistent infection
does not seem to playa critical role in the develop-
ment of renal scarring, because kidneys from pa-
tients with CPN are often sterile at autopsy [1, 2].
In experimental pyelonephritis, viable bacteria are
not required for progression of the lesions [3-5].
Furthermore, bacterial antigens persisting in the
late phase of human and experimental pyelone-
phritis [2, 6, 7] have been shown not to trigger
significant kidney destruction [6, 7]. Two other
immune mechanisms have been proposed. Either
alterations in antigenicity of kidney tissue [8] or
common antigens which are shared by Escherichia
coli and renal tissue [9] have been postulated to
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stimulate a chronic, destructive immune response.
However, the demonstration of antibodies to
kidney tissue in CPN has been unsuccessful so far,
both in humans [10] and in experimental animals
[11]. Thymus-dependent autoimmune phenomena
have been shown not to play a significant role in
the development of CPN in rats [5, 12]. In fact,
athymic, nude mice challenge iv with Streptococ-
cus faecalis seem to develop more intense kidney
infection and scarring than their normal litter-
mates [13].
To investigate the mechanisms that lead to
CPN, we have used a model of ascending obstruc-
tive pyelonephritis due to E. coli that resembles se-
vere human kidney infection because the disease is
acquired by the retrograde route in the presence of
an obstruction [14]. Previous experiments in
which rats were treated with antibiotics starting at
different times during acute pyelonephritis have
suggested that the acute inflammatory process
plays a major role in the development of kidney
scars leading to CPN and that infection seems less
important [5]. In those studies, however, the di-
minished inflammation by early treatment might
have been due to bacterial inhibition by antibio-
tics. During inflammatory processes, polymor-
phonuclear leukocytes (PMNLs) can damage
tissue by exocytosis of lysosomal enzymes.
Therefore, we gave rats with acute pyelonephritis
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either colchicine, thus impairing PMNL move-
ment, or cyclophosphamide, thus inducing severe
neutropenia.
Materials and Methods
Induction ofpyelonephritis. Retrograde pyelo-
nephritis was induced in male Wistar rats weighing
200-250 g (Madorin, Fiillingsdorf, Switzer-
land) [14]. In brief, 103 E. coli type 06 organisms
(Williams strain) [14] were slowly infused into the
bladder and a ligature was loosely tied around the
left ureter; 18 hr later the ligature was removed.
This procedure produces partial obstruction
followed by severe unilateral pyelonephritis.
Three days after this operation, the pyelonephritic
kidneys are greatly enlarged and display numerous
abcesses over the cortex [14]. Two months after
the operation, the kidneys have extended scars
with severe destruction of kidney parenchyma
[14].
Experimental design and killing ofrats. In this
model of pyelonephritis, inflammation, as mea-
sured by the ratio of the weight of the left pyelone-
phritic kidney to that of the right normal kidney,
reaches a peak three days after the operation and
bacterial inoculation [5]. Colchicine-treated,
neutropenic, and control rats were killed at this
time in order to evaluate the effect of colchicine
and neutropenia on acute pyelonephritis. The
kidneys were examined for gross evidence of
acute pyelonephritis after three days or for scars
of CPN after two months. The distribution of
abscesses or scars on the surface of the kidney was
graded by dividing the kidney into eight equal
parts and counting the number of parts where
there was at least one abscess or scar. A distribu-
tion index was calculated from the sum of the
number of parts having abscesses or scars [14].
The kidneys were weighed and cut in half; one half
was homogenized in 0.85070 NaCI and serially di-
luted before plating onto MacConkey's agar (Dif-
co Laboratories, Detroit) for colony counts ex-
pressed in log cfu. The other half of each kidney
was processed for histologic examination.
Severity ofpyelonephritis. Kidney weight pro-
vides the best quantitative measure of the severity
of pyelonephritis - it increases in proportion to
suppuration during acute obstructive pyelone-
phritis, whereas it decreases in proportion to the
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destruction of kidney tissue during CPN [15]. To
minimize the effects of variation of kidney weights
among animals, the ratio of the left kidney weight
to the right kidney weight (the L: R weight ratio)
was used [5]. This is especially important when
dealing with long-term experiments, wherein the
total body weight may vary greatly among
animals. The L: R weight ratio also expresses the
compensatory hypertrophy of the right kidney
during CPN, which is proportional to the destruc-
tion and shrinkage of the left kidney [15].
Administration ofcolchicine. Colchicine pow-
der (Fluka, Buochs, Switzerland) was diluted
in sterile water to a concentration of 1 mg/ml.
Colchicine was administered ip daily to the rats in
a dosage of 0.4 mg/kg of body weight per day for
three consecutive days. The first injection was
given one day before the operation. Control rats
were given one injection of 0.1 ml of 0.85% NaCI
ip daily for three consecutive days.
Administration of cyclophosphamide and in-
duction of neutropenia. Cyclophosphamide pow-
der (Endoxan; Asta Werke, Bielefeld, Federal Re-
public of Germany) was diluted in sterile water to
a concentration of 25 mg/ml. Cyclophosphamide
was given ip to the rats four days before the opera-
tion in a dose of 100 mg/kg of body weight. Con-
trol rats were given 1.0 ml of 0.85% NaCI ip. Leu-
kocyte counts of the tail blood were made with a
hemacytometer.
Statistical evaluation. The number of cfu/g of
kidney, the L: R weight ratio of the kidneys, and
the surface area of the kidney occupied by ab-
scesses were compared by Student's unpaired
r-test.
Results
Effect of colchicine treatment on pyelonephri-
tis. Colchicine treatment was associated with
early mortality in the rats receiving the drug. Dur-
ing the first three days after the operation, seven
(14%) of 49 colchicine-treated rats died, four in
the acute and three in the chronic pyelonephritis
experiments. No deaths occurred in the control
rats. The severity of the disease in the dead ani-
mals as measured by the L : R weight ratio, the dis-
tribution of macroscopic lesions, and the bacterial
counts were not different from those observed in
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Bacterial count (log cfu/g)
Acute phase (three days after induction) Chronic phase (two months after induction)
Colchicine-treated Colchicine-treated
Control (n = 14) (n = 18) P Control (n = 18) (n = 24) P
1.77 ± 0.3 1.56 ± 0.2 0.02 0.35 ± 0.1 0.48 ± 0.2 0.02
5.3 ± 2.1 6.5 ± 1.4 NS 6.61 ± 1.4 5.50 ± 2.2 NS
7.60 ± 1.2 8.40 ± 0.8 0.031 3.84 ± 2.3 3.19 ± 2.5 NS
NOTE. Colchicine (0.4 mg/kg of body weight per day) was administered ip to rats for three days beginning one day before pye-
lonephritis was induced in the left kidney by operation [14]. Control rats were given one ip injection of 0.1 ml of 0.85010 NaCI per
day for three days. Three days after the operation, the ratio of the weight of the left kidney to the weight of the right kidney (L:R
weight ratio) was calculated to measure the intensity of the inflammation of the left kidney. Two months later, the L:R weight ratio
was calculated to express the destruction of tissue in the left kidney. The surface of the left kidney was divided into eight equal sec-
tions and the distribution index was defined as the number of sections with one or more abscesses or scars. Infection was expressed
as the log of the number of cfu of Escherichia coli type 06/g of left kidney homogenate. Data are means ± SD. NS = not significant.
colchicine-treated rats that were killed at the same
time.
Table 1 compares pyelonephritis in colchicine-
treated rats and control rats. When expressed by
the L: R weight ratio, acute inflammation was
slightly but significantly reduced in colchicine-
treated rats. The distribution of lesions on the sur-
face of the left kidney in the colchicine-treated rats
was not different from that in the control rats, but
the gross abscesses were smaller. In contrast to the
reduction of L: R weight ratio, the bacterial
counts in the kidneys were significantly higher in
colchicine-treated rats than in the control rats.
Table 1 also shows the long-term effect of col-
chicine treatment. There was significant protec-
tion of the colchicine-treated rats against the
parenchymal destruction of the pyelonephritic
kidney compared with the control animals. De-
spite a similar distribution of scars at the surface
of the kidney, scars were smaller and less numer-
ous in colchicine-treated rats. Bacterial counts
were similar in both groups of rats after two months.
Effect of neutropenia on pyelonephritis. Ad-
ministration of cyclophosphamide four days be-
fore the operation resulted in severe leukopenia
and neutropenia at the time of the operation and
bacterial inoculation. The mean ± SD leukocyte
count in the peripheral blood was reduced from
9,300 ± 2,800 cells/rum" in the control rats to
1,010 ± 360 cells/rnrn" on the day of the opera-
tion, to 820 ± 380 cells/rum" the following day
(coinciding with the end of the ureteral obstruc-
tion), and to 1,780 ± 930 cells/rum" two days
after the operation. No circulating PMNLs were
found on the first two days after the operation.
Cyclophosphamide treatment was accompanied
by 22010 mortality (five of 25 rats) during the first
three days after the operation. No deaths occurred
in the control rats. Pyelonephritis in the dead ani-
mals as measured by the L: R weight ratio of the





Bacterial count (log cfu/g)
Acute phase (three days after induction) Chronic phase (two months after induction)
Cyclophosphamide- Cyclophosphamide-
Control (n = 21) treated (n = 9) P Control (n = 24) treated (n = 10) P
2.03 ± 0.3 1.63 ± 0.3 0.0023 0.31 ± 0.15 0.50 ± 0.2 0.0085
5.5 ± 2.1 6.05 ± 1.6 NS 6.64 ± 2.0 6.96 ± 1.4 NS
8.29 ± 1.0 9.45 ± 1.1 0.086 3.43 ± 2.0 4.26 ± 2.3 NS
NOTE. Cyclophosphamide (100 mg/kg of body weight) was administered ip to rats four days before pyelonephritis was in-
duced in the left kidney by operation [14]. Control rats were given 1.0 ml of 0.85% NaCI ip at the same time. Three days after the
operation, the ratio of the weight of the left kidney to the weight of the right kidney (L:R weight ratio) was calculated to measure the
intensity of the inflammation of the left kidney. Two months later, the L:R weight ratio was calculated to express the destruction of
tissue in the left kidney. The surface of the left kidney was divided into eight equal sections, and the distribution index was defined
as the number of sections with one or more abscesses or scars. Infection was expressed as the log of the number of cfu of Escherichia
coli type 06/g of left kidney homogenate. Data are means ± SD. NS = not significant.
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kidneys, the distribution of macroscopic lesions,
and the bacterial counts was not different from
that in surviving neutropenic rats killed at the
same time. Table 2 compares pyelonephritis in
neutropenic and control rats. When expressed by
the L: R weight ratio, inflammation during the
acute phase of the disease was reduced in the
cyclophosphamide-treated rats compared with
that in control rats. In contrast, the bacterial
counts were significantly higher.
As in the colchicine experiments, the distribu-
tion of abscesses over the renal cortical surface
was similar in neutropenic and control rats, but
the size and the number of abscesses was markedly
reduced. This striking difference is shown in
figure 1.
After two months of infection, cyclophospha-
mide-treated rats displayed a significant reduction
in parenchymal destruction and scarring, despite a
slightly higher number of residual bacteria. Fur-
thermore, although the distribution of scars was
similar to that in control rats, the scars were
smaller and fewer.
Microscopic examinations of sections of acutely
infected kidneys showed dramatic differences be-
tween neutropenic rats and control rats. Control
rats had many large abscesses containing innumer-
able PMNLs . Single abscesses extended from the
medulla through the cortex and invariably
distended the overlying capsule. Lesions in
neutropenic animals which looked macroscopical-
ly like abscesses, appeared microscopically to con-
tain masses of bacteria within distended tubules,
but contained only a few PMNLs. These lesions
were smaller and seldom distended the overlying
capsule. Thus, lesions in acute pyelonephritis in
neutropenic rats were both fewer and quite differ-
ent in microscopic appearance from those in con-
trol rats. These histologic differences probably ac-
counted for the differences in kidney weight.
Despite differences in kidney weight during the
acute phase, the histology of the scars examined
two months after the operation was similar in cy-
clophosphamide-treated and control rats.
Discussion
Previous studies of the pathogenesis of CPN after
acute, ascending, obstructive pyelonephritis in the
rat [5] have suggested that acute inflammation and
suppuration determined the severity of residual
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Figure 1. Control (left) and acutely pyelonephritic
(right) kidneys from (top) untreated and (bottom) neu-
tropenic rats . Cyclophosphamide was given to rats four
days before the induction of pyelonephritis to induce
severe leukopenia and neutropenia.
renal scarring. If the peak of inflammation was
prevented by early antibiotic therapy, very little
parenchymal destruction occurred. Even if low
doses of antibiotic sufficient to suppress acute in-
flammation but not to sterilize the kidney were
given, little scarring developed despite persistent
infection throughout the course of the disease.
Moreover, if antibiotic treatment was started after
the peak inflammatory process had fully devel-
oped, severe renal destruction and CPN evolved in
the absence of bacteria. These two observations
suggest that the bacteria themselves act only to in-
cite the acute inflammatory response and there-
after play an insignificant role in the development
of CPN. Similar observations stressing the need
for early antibiotic treatment to prevent renal
scars have been recently made by other in-
vestigators [16].
In the antibiotic experiments mentioned above
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[5], the dramatic protection against CPN might
have been due to decreased endotoxin release by
antibiotic suppression of bacterial growth. The in-
trarenal injection of dogs with lipid A, the toxic
component of lipopolysaccharide endotoxins of
gram-negative bacteria, produces an inflamma-
tory response that is related to the dose of lipid A
[17]. In the present report, colchicine treatment
and cyclophosphamide-induced neutropenia di-
minished the peak of inflammation during acute
pyelonephritis, but renal bacterial counts were
higher throughout the course of acute-to-chronic
pyelonephritis. If bacterial infection itself or the
release of endotoxin directly injures the renal par-
enchyma, more severe CPN should be found in
the neutropenic or colchicine-treated rats than in
control rats. Instead, we found less severe CPN
despite higher bacterial counts. Decreased inflam-
mation during the acute phase of suppurative
pyelonephritis, not depressed bacterial growth,
protected against kidney destruction in the chronic
phase of the disease.
PMNLs are a crucial element in acute inflam-
mation. Under various stimuli that are normally
encountered during inflammation, PMNLs release
substances that injure tissues. [18, 19]. Studies of
acute myocardial infarction in rats have shown
that tissue damage is directly related to PMNL in-
filtration and is reduced by measures which inhibit
exudation [20]. In gouty arthritis, inflammation is
mainly mediated by the release of inflammatory
substances from PMNLs actively phagocytosing
urate crystals [21]. Colchicine has been used for
centuries to treat this condition. Its anti-inflam-
matory effect has been shown to be due to inter-
ference with leukocyte locomotion and chemo-
taxis and to diminished lysosomal degranulation
[22]. In experimental pyogenic infection [23], col-
chicine has been shown to delay the delivery of
PMNLs to the site of infection and thus reduce
inflammation. However, infection was more
severe in these experiments, at least in part
because of the delay in delivery of leukocytes. Col-
chicine acted similarly in acute pyelonephritis in
rats in the present study. The inflammatory pro-
cesses as measured by the L: R weight ratios of the
kidneys were reduced after colchicine treatment,
whereas bacterial counts increased. This resulted
in reduced parenchymal destruction in the chronic
phase, suggesting that the toxic and tissue-destruc-
tive processes during acute inflammation could be
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in part due to infiltration of leukocytes that was
more important than infection in the pathogenesis
of renal scars.
Whereas colchicine treatment provided indirect
support for a crucial role of PMNLs in the patho-
genesis of renal scarring, experiments in rats ren-
dered neutropenic during acute pyelonephritis
provided more direct evidence. It has been shown
in another model of acute pyelonephritis that
complement depletion by means of cobra venom
factor results in diminished exudation of PMNLs
in the renal parenchyma and preserves the mor-
phology of the kidney [24]. More recently, Shima-
mura [25] observed a direct relationship between
infiltration of PMNLs and renal tissue damage
during the first two days of renal infection in
neutropenic rats. In our neutropenic rats with
acute pyelonephritis, infection in the kidneys was
as widespread as in the control rats but was less
severe as judged by smaller abscess size, lower kid-
ney weight, and much less infiltration of PMNLs.
In addition, renal scarring two months later was
diminished.
Because treatments with colchicine and cyclo-
phosphamide were accompanied by some mortal-
ity, we explored the possibility that both drugs
could influence food and water intake. We won-
dered if the reduced inflammation found during
acute pyelonephritis could have been due to dehy-
dration resulting from diminished water intake.
This was not the case, because pyelonephritic rats
housed in metabolic cages and given the same
amount of food and water as taken by cyclophos-
phamide-treated rats had as severe pyelonephritis
as control rats fed as much as they wanted.
Experiments by Miller et al. [26] using cyclo-
phosphamide to treat pyelonephritis in rats illus-
trates the role of early infiltration by PMNLs in
the pathogenesis of renal scars. In these experi-
ments, cyclophosphamide was administered two
and four days after initiating renal infection. The
resulting neutropenia, which was delayed in rela-
tion to the peak of inflammation, did not prevent
renal scars. The contrast between our results and
those with delayed induction of neutropenia sup-
port the view that initial infiltration by PMNLs
produces the renal injury that ultimately results in
CPN.
Cyclophosphamide might prevent renal scars by
suppression of humoral or cellular immune mech-
anisms responsible for renal parenchymal dam-
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age. Indeed, next to its immediate leukopenic ef-
fect, cyclophosphamide has a profound effect on
both T and B lymphocytes [27]. However, exten-
sive investigation has not shown a role for humor-
al immunity in the pathogenesis of CPN [2, 5-7,
10, 11]. In the present report, E. coli agglutinin
levels measured two months after infection were
similar in cyclophosphamide-treated and in con-
trol pyelonephritic rats (mean ± SD 10g2 serum
titer, 19.8 ± 1.8 and 20.2 ± 2.4, respectively).
Thus, it seems unlikely that parenchymal damage
was prevented by diminished antibody produc-
tion. Cellular immune mechanisms have been
shown not to be responsible for kidney damage
during renal infection [12, 28]. Furthermore, in our
model, rats thymectomized at birth showed no dif-
ference in the extent of CPN from that observed in
sham-thymectomized rats [5]. If cyclophospha-
mide given just before infection in our experi-
ments had acted by preventing a cellular immune
mechanism, the administration of the drug just
after initiation of infection as done by Miller et al.
[26] should have also diminished renal scars. Be-
cause this was not the case, it reinforces our inter-
pretation that PMNLs, rather than cellular or hu-
moral immunity, mediate tissue damage during
the inflammatory processes resulting from infec-
tion in the kidney.
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